Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Tobacco Use Disorder 1Smoking Cessation 1Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lung Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Behavior 1

Interventions

pembrolizumab 3Ipilimumab 3Educational Status 3Biopsy 3Optical Imaging 2Nivolumab 2Early Intervention, Educational 2Ascorbic Acid 2methyl 5-aminolevulinate 1lavender oil 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1fludarabine 1aldesleukin 1Zinc 1Water 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tomography, Optical Coherence 1Toll-Like Receptor 1 1Tea 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Spermine Synthase 1Specimen Handling 1Semaxinib 1Second Harmonic Generation Microscopy 1Risk Factors 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Skin Neoplasms × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡